T. Rowe Price Group, Inc.TROW announced preliminary assets under management (AUM) of $1.02 trillion for April 2018. Results reflect nearly 1% rise from $1.01 trillion recorded on Mar 31, 2018.
Client transfers from mutual funds to other portfolios of $2.5 billion were recorded in April 2018.
Month-end total sponsored U.S. mutual funds came in at $614 billion, slightly up from the prior month. Of the total sponsored U.S. mutual funds, around 79% were from stock and blended assets while the remaining came from bond and money market.
Total other investment portfolios were $406 billion, reflecting an increase of 1.2% from the previous month. Overall, stock and blended assets accounted for $309 billion or 76% of other investment portfolios while bond, money market and stable value came in at $97 billion or 24%.
T. Rowe Price recorded $241 billion in target date retirement portfolios, which was slightly up from $240 billion recorded in the prior month.
Although regulatory restrictions and sluggish economic recovery are likely to impair the company's growth and escalate costs, T. Rowe Price's diverse and efficient business model is anticipated to help it further improve AUM. Also, its organic growth remains impressive, as indicated by the continuous rise in revenues.
So, we believe, driven by these, shares of T. Rowe Price have gained 25.3% in the last six months, outperforming 1.6% rally of the industry .
T. Rowe currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Among other investment managers, Franklin Resources BEN has announced preliminary AUM by its subsidiaries of $732.5 billion for April 2018. Results display nearly 1% drop from $737.5 billion recorded as of Mar 31, 2018. Net outflows were primarily responsible for the decline but were partially offset by market appreciation. Further, the figure fell 1.1% from the prior year.
Legg Mason Inc. LM reported a slight fall in AUM as of Apr 30, 2018 from the prior month. Preliminary month-end AUM came in at $752.3 billion, down from the March 2018 figure of $754.1 billion.
Invesco Ltd. IVZ reported preliminary month-end AUM of $972.8 billion for April 2018. The figure reflects an increase of 4.1% from the prior month. The rise was mainly driven by the Guggenheim acquisition, favorable market returns, improvement in money market AUM and reinvested distributions. These were partially offset by net long-term outflows and non-management fee earning AUM outflows.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportT. Rowe Price Group, Inc. (TROW): Free Stock Analysis ReportInvesco Ltd. (IVZ): Free Stock Analysis ReportLegg Mason, Inc. (LM): Free Stock Analysis ReportFranklin Resources, Inc. (BEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research